Company profile for Vast Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company focused on helping patients who suffer from severe respiratory diseases to breath better and live life more fully. The company is being purpose-built using our proprietary nitric oxide platform technology. These preclinical assets are licensed from Novan (NASDAQ:NOVN) and were developed in collaboration with Dr. Mark Schoenfisch’s lab at UNC Chapel ...
Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company focused on helping patients who suffer from severe respiratory diseases to breath better and live life more fully. The company is being purpose-built using our proprietary nitric oxide platform technology. These preclinical assets are licensed from Novan (NASDAQ:NOVN) and were developed in collaboration with Dr. Mark Schoenfisch’s lab at UNC Chapel Hill.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4222 Emperor Blvd #470, Durham, NC 27703, USA
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/vast-therapeutics-completes-first-milestone-in-phase-1-clinical-program-302617782.html

PR NEWSWIRE
18 Nov 2025

https://www.prnewswire.com/news-releases/vast-granted-qualified-infectious-disease-product-designation-from-the-fda-302411166.html

PR NEWSWIRE
25 Mar 2025

https://www.prnewswire.com/news-releases/vast-awarded-2-million-grant-to-combat-deadly-respiratory-bacteria-302356209.html

PR NEWSWIRE
21 Jan 2025

https://www.prnewswire.com/news-releases/vast-therapeutics-selected-to-present-at-the-american-thoracic-society-ats-2024-respiratory-innovation-summit-302119594.html

PR NEWSWIRE
17 Apr 2024

https://www.prnewswire.com/news-releases/vast-therapeutics-announces-publication-of-potential-new-treatment-for-non-tuberculosis-mycobacteria-infections-302037119.html

PR NEWSWIRE
17 Jan 2024

https://www.prnewswire.com/news-releases/vast-therapeutics-presents-promising-preclinical-results-for-novel-treatment-for-ntm-disease-301579761.html

PRNEWSWIRE
01 Jul 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty